» Articles » PMID: 35810317

Virological Outcomes and Risk Factors for Non-suppression for Routine and Repeat Viral Load Testing After Enhanced Adherence Counselling During Viral Load Testing Scale-up in Zimbabwe: Analytic Cross-sectional Study Using Laboratory Data from 2014...

Abstract

Background: Since the scale-up of routine viral load (VL) testing started in 2016, there is limited evidence on VL suppression rates under programmatic settings and groups at risk of non-suppression. We conducted a study to estimate VL non-suppression (> 1000 copies/ml) and its risk factors using "routine" and "repeat after enhanced adherence counselling (EAC)" VL results.

Methods: We conducted an analytic cross-sectional study using secondary VL testing data collected between 2014 and 2018 from a centrally located laboratory. We analysed data from routine tests and repeat tests after an individual received EAC. Our outcome was viral load non-suppression. Bivariable and multivariable logistic regression was performed to identify factors associated with having VL non-suppression for routine and repeat VL.

Results: We analysed 103,609 VL test results (101,725 routine and 1884 repeat test results) collected from the country's ten provinces. Of the 101,725 routine and 1884 repeat VL tests, 13.8% and 52.9% were non-suppressed, respectively. Only one in seven (1:7) of the non-suppressed routine VL tests had a repeat test after EAC. For routine VL tests; males (vs females, adjusted odds ratio (aOR) = 1.19, [95% CI 1.14-1.24]) and adolescents (10-19 years) (vs adults (25-49 years), aOR = 3.11, [95% CI 2.9-3.31]) were more at risk of VL non-suppression. The patients who received care at the secondary level (vs primary, aOR = 1.21, [95% CI 1.17-1.26]) and tertiary level (vs primary, aOR = 1.63, [95% CI 1.44-1.85]) had a higher risk of VL non-suppression compared to the primary level. Those that started ART in 2014-2015 (vs < 2010, aOR = 0.83, [95% CI 0.79-0.88]) and from 2016 onwards (vs < 2010, aOR = 0.84, [95% CI 0.79-0.89]) had a lower risk of VL non-suppression. For repeat VL tests; young adults (20-24 years) (vs adults (25-49 years), (aOR) = 3.48, [95% CI 2.16 -5.83]), adolescents (10-19 years) (vs adults (25-49 years), aOR = 2.76, [95% CI 2.11-3.72]) and children (0-9 years) (vs adults (25-49 years), aOR = 1.51, [95% CI 1.03-2.22]) were at risk of VL non-suppression.

Conclusion: Close to 90% suppression in routine VL shows that Zimbabwe is on track to reach the third UNAIDS target. Strategies to improve the identification of clients with high routine VL results for repeating testing after EAC and ART adherence in subpopulations (men, adolescents and young adolescents) at risk of viral non-suppression should be prioritised.

Citing Articles

Incidence Rate, Survival Rate, and Predictors for Virological Failure Among Adult TB/HIV Coinfected Clients.

Muhie N J Trop Med. 2025; 2025:2011556.

PMID: 39990258 PMC: 11846676. DOI: 10.1155/jotm/2011556.


HIV viral load suppression rates among adults and children living with HIV in the North West Region of Cameroon: A call for action!.

Tayong G, Sander M, Vuchas C, Samje M, Kum V, Enokbonong P PLoS One. 2025; 20(1):e0316399.

PMID: 39888931 PMC: 11785274. DOI: 10.1371/journal.pone.0316399.


Factors associated with viral load re-suppression after enhanced adherence counseling among people living with HIV with an initial high viral load result in selected Nigerian states.

Obasa G, Ijaiya M, Okwor E, Dare B, Emerenini F, Oladigbolu R PLOS Glob Public Health. 2024; 4(11):e0002876.

PMID: 39576774 PMC: 11584108. DOI: 10.1371/journal.pgph.0002876.


Viral load non-suppression among adolescents and youth living with HIV in South Africa.

Molopa L, Ginyana T, Vondo N, Magobo R, Maseko G, Zungu N S Afr J Infect Dis. 2024; 39(1):629.

PMID: 39364331 PMC: 11447573. DOI: 10.4102/sajid.v39i1.629.


Clinical-epidemiological profile and factors associated with viral non-suppression in patients living with HIV/AIDS assisted at the Integrated Treatment Center at the Maputo Military Hospital (CITRA/MMH), 2019 to 2020.

Chicanequisso E, Sema Baltazar C, Sacarlal J BMC Infect Dis. 2024; 24(1):713.

PMID: 39033267 PMC: 11265015. DOI: 10.1186/s12879-024-09616-2.


References
1.
Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G . Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017; 17(1):326. PMC: 5415758. DOI: 10.1186/s12879-017-2428-3. View

2.
El-Sadr W, Rabkin M, Nkengasong J, Birx D . Realizing the potential of routine viral load testing in sub-Saharan Africa. J Int AIDS Soc. 2017; 20 Suppl 7. PMC: 5978658. DOI: 10.1002/jia2.25010. View

3.
Hirasen K, Fox M, Hendrickson C, Sineke T, Onoya D . HIV Treatment Outcomes Among Patients Initiated on Antiretroviral Therapy Pre and Post-Universal Test and Treat Guidelines in South Africa. Ther Clin Risk Manag. 2020; 16:169-180. PMC: 7061415. DOI: 10.2147/TCRM.S227290. View

4.
Ndagijimana Ntwali J, Decroo T, Ribakare M, Kiromera A, Mugwaneza P, Nsanzimana S . Viral load detection and management on first line ART in rural Rwanda. BMC Infect Dis. 2019; 19(1):8. PMC: 6318862. DOI: 10.1186/s12879-018-3639-y. View

5.
Dorward J, Sookrajh Y, Gate K, Khubone T, Mtshaka N, Mlisana K . HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study. J Int AIDS Soc. 2020; 23(4):e25479. PMC: 7174836. DOI: 10.1002/jia2.25479. View